Ibrutinib As a Salvage Therapy in Progressing Chronic Lymphocytic Leukemia After Venetoclax Treatment in Ibrutinib Naïve Patients
Latest Information Update: 09 Dec 2019
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 09 Dec 2019 New trial record
- 06 Nov 2019 Results (N=27), assessing outcome treatment (efficacy and safety) of Ibrutinib after disease progression post Venetoclax therapy in patients with Chronic Lymphocytic Leukemia (CLL) retrospectively, released at the 61st Annual Meeting and Exposition of the American Society of Hematology